|
Market Closed -
Toronto S.E.
22:59:59 02/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 12.01 CAD | -0.66% |
|
-3.92% | +51.64% |
Company Valuation: Satellos Bioscience Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6.794 | 36.73 | 95.65 | 89.3 | 178.7 | - | - |
| Change | - | 440.53% | 160.46% | -6.65% | 100.18% | - | - |
| Enterprise Value (EV) 1 | 6.794 | 36.73 | 46.68 | 89.3 | 77.15 | 59.75 | -8.453 |
| Change | - | 440.53% | 27.11% | 91.29% | -13.6% | -22.55% | -114.15% |
| P/E | - | - | -3.32x | -3.36x | -4.07x | -5.45x | -5.5x |
| PBR | - | - | - | - | 5.09x | 4.01x | - |
| PEG | - | - | - | 0.2x | -0.2x | 0.2x | 6.12x |
| Capitalization / Revenue | - | - | - | - | - | - | 31.6x |
| EV / Revenue | - | - | - | - | - | - | -1.49x |
| EV / EBITDA | - | - | - | -3.38x | -3.09x | -2.15x | 0.3x |
| EV / EBIT | -1.08x | -3.23x | -2.4x | -3.37x | -1.67x | -1.19x | 0.16x |
| EV / FCF | - | - | -2.67x | - | -1.83x | -1.58x | 0.16x |
| FCF Yield | - | - | -37.5% | - | -54.5% | -63.3% | 615% |
| Dividend per Share 3 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 3 | - | - | -3 | -2.354 | -2.949 | -2.205 | -2.186 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 5.66 |
| EBITDA 1 | - | - | - | -26.46 | -25 | -27.75 | -28 |
| EBIT 1 | -6.268 | -11.38 | -19.45 | -26.46 | -46.14 | -50.27 | -51.46 |
| Net income 1 | -8.368 | -11.69 | -19.65 | -24.87 | -49.74 | -61.15 | -72.69 |
| Net Debt 1 | - | - | -48.97 | - | -101.6 | -119 | -187.2 |
| Reference price 3 | 2.64 | 5.16 | 9.96 | 7.92 | 12.01 | 12.01 | 12.01 |
| Nbr of stocks (in thousands) | 3,483 | 9,399 | 13,818 | 15,459 | 21,216 | - | - |
| Announcement Date | 3/30/23 A | 3/27/24 A | 3/26/25 A | 3/27/26 A | - | - | - |
1CAD in Million2USD in Million3CAD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.07x | - | -3.09x | - | 179M | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 18.47x | 31.37x | 10.92x | 0.31% | 39.07B | |
| Weighted average by Cap. | 22.26x | 32.04x | 13.54x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MSCL Stock
- Valuation Satellos Bioscience Inc.
Select your edition
All financial news and data tailored to specific country editions
